Pivotal Study of the SUpira System in Patients Undergoing High-Risk Percutaneous COronaRy InTervention (HRPCI)

Recruiting now · Not applicable

Conditions studied: Coronary Artery Disease, High Risk Percutaneous Coronary Intervention, Interventional Cardiology, Mechanical Circulatory Support

In brief

The objective of this study is to assess the safety and efficacy of the Supira System in providing temporary cardiovascular hemodynamic support in patients undergoing HRPCI. Eligible patients will be randomized to undergo HRPCI with either the Supira System (investigational device) or the commercially available Impella systems (comparator device).

Key facts

Study ID

NCT07296744

Run by

Supira Medical

People needed

358

Starts

2026-05-11

Expected to finish

2027-11-01

Last updated by the study team

2026-07-08

Who can join

Age: 18 and older, up to 90. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Hemodynamically stable and will undergo elective or urgent (not emergent) HRPCI, where hemodynamic support is deemed necessary, as determined by the institutional Heart Team
• Informed consent granted by the subject or legally authorized representative

You may not qualify if…

• Cardiogenic shock or acutely decompensated pre-existing chronic heart failure
• Stroke within 6 months of the index procedure, or any prior stroke with permanent neurologic deficit
• Left ventricular thrombus
• Aortic and iliofemoral anatomical conditions that preclude safe delivery and placement of the investigational device or the comparator device
• Ongoing renal replacement therapy with dialysis
• Presence of decompensated liver disease; severe liver dysfunction
• Infection of the proposed procedural access site or active infection
• Known hypersensitivity to intravenous contrast agents that cannot be adequately pre-medicated or known hypersensitivity to heparin, aspirin, adenosine diphosphate (ADP) receptor inhibitors, or nitinol
• Any condition, coagulopathy, planned procedure or contraindication that requires discontinuation of antiplatelet and/or anticoagulant therapy within 90 days of the index procedure
• Breastfeeding or pregnant or planning to become pregnant within 90 days of the HRPCI procedure
• Currently participating in active follow-up phase of another clinical study of an investigational drug or device or planning to enroll in such a study within 90 days of the HRPCI procedure
• Other medical, social, or psychological problems that, in the opinion of the Investigator, compromises the subject's ability to provide written informed consent and/or to comply with study procedures
• Considered to be part of a vulnerable population per the investigator's assessment

Where it is running

• Baylor Scott & White The Heart Hospital — Plano, Texas, United States (enrolling)
• UC Davis — Sacramento, California, United States (enrolling)
• Cuimc/Nyph — New York, New York, United States (enrolling)
• Montefiore Medical Center — The Bronx, New York, United States (enrolling)
• OhioHealth — Columbus, Ohio, United States (enrolling)
• Oklahoma Heart Hillcrest Medical — Tulsa, Oklahoma, United States (enrolling)
• Wellspan York Hospital — York, Pennsylvania, United States (enrolling)
• Prisma Health — Columbia, South Carolina, United States (enrolling)
• Piedmont Heart Institute — Atlanta, Georgia, United States (enrolling)
• Henry Ford Health / St. John Hospital — Detroit, Michigan, United States (enrolling)
• CentraCare — Saint Cloud, Minnesota, United States (enrolling)
• Washington University in St. Louis — St Louis, Missouri, United States (enrolling)
• University of Buffalo (Buffalo General) — Buffalo, New York, United States (enrolling)
• Los Robles Regional Medical Center — Thousand Oaks, California, United States
• OHSU — Portland, Oregon, United States
• Emory University Hospital — Atlanta, Georgia, United States
• Northwestern University — Chicago, Illinois, United States
• University of Pennsylvania — Philadelphia, Pennsylvania, United States
• Loma Linda University Medical Center — Loma Linda, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.